Search Results
Your search for them matches 6128 pages
Showing 2401 - 2450Databases: Where Math Meets Medicine
About 4 decades ago, as a young physician, I observed that most surgeons were numerator doctors; they remembered their successes and their failures, but they did not remember the frequency of either. There was no denominator. Worse, the approach to any specific surgical problem was always the...
ASH 2019: Genomic Features of AML in Patients Aged 60 or Older May Predict Stem Cell Transplant Outcome
For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of leukemic genetic characteristics, according to results presented by Murdock et al at the 2019 American Society of Hematology (ASH) Annual...
ASH 2019: CAR T-Cell Therapy Shows Activity, Reduces Health-Care Utilization in Older Patients With DLBCL
A new analysis of Medicare claims data presented by Kilgore et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 793) has provided the first real-world evidence using claims data available after the approval of autologous anti-CD19 chimeric antigen...
ASH 2019: Is Autologous Hematopoietic Stem Cell Transplant Safe and Effective for Patients Aged 70 or Older With Multiple Myeloma?
Even though autologous hematopoietic stem cell transplantation (AHCT) is an effective treatment for multiple myeloma, only 4 out of 10 patients receive this therapy. A new study presented by Munshi et al at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 782) ...
ASH 2019: Lower Area-Based Income and Educational Attainment Associated With Poorer Survival Among Pediatric Patients With AML
Children from lower-income neighborhoods were 2.4 times more likely to die during treatment for acute myeloid leukemia (AML) than children from middle- and high-income neighborhoods, according to findings from a study that analyzed nearly 1,500 clinical trial participants. While previous research...
ASH 2019: Dose-Climbing Trial of Dual-Target CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma
More than three out of four patients with relapsed multiple myeloma, or myeloma that was refractory to at least two therapies, remained in remission 7 months after treatment with a novel chimeric antigen receptor (CAR) T-cell therapy targeting two proteins that are frequently found on myeloma...
ASH 2019: Early Data Signal Potential for Bispecific Antibody in Non-Hodgkin Lymphoma
The investigational bispecific antibody mosunetuzumab is showing activity in preliminary studies of patients with non-Hodgkin lymphoma (NHL), including those who are refractory to or relapsed after third-line chimeric antigen receptor (CAR) T-cell therapy. If preliminary findings are validated by...
Promising New Treatments for Triple-Negative Breast Cancer: Immunotherapy and Other Targeted Therapies
Clinical trials continue to demonstrate that combining immunotherapy with chemotherapy and other targeted therapies can improve survival for patients with triple-negative breast cancer, according to results presented at the 21st Annual Lynn Sage Breast Cancer Symposium in Chicago. Nearly 700...
Multidimensional Palliative Care: Fewer Opioids, More Pain Control in Patients With Advanced Cancer
For opioid-tolerant patients with advanced cancer experiencing pain, relief does not necessarily have to come from a higher dose of opioids, according to findings presented at the 2019 Supportive Care in Oncology Symposium.1 The results of a retrospective analysis of 300 patients with advanced...
Is Nonmetastatic Castration-Resistant Prostate Cancer a Valid Disease Category?
Does nonmetastatic castration-resistant prostate cancer really exist? Although it is considered a disease category, it turns out that the definition depends on the type of imaging used. Many patients with castration-resistant prostate cancer who were categorized as “nonmetastatic” on conventional...
Role of Integrative Therapies for Patients With Colorectal Cancer
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Richard T. Lee, MD, describes the symptoms associated with colorectal cancer...
Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer
In the post-trastuzumab era, a number of U.S. Food and Drug Administration (FDA)-approved targeted agents for metastatic HER2-positive breast cancer are available, but there is no preferred option for third-line treatment and beyond. At the 2019 Chemotherapy Foundation Symposium, Shanu Modi, MD,...
Assessing Cancer Pain Management in the Era of the Opioid Epidemic
A vast majority of patients with cancer receiving opioids for the management of pain will adhere to the opioids as prescribed and will have no major difficulties with dose reduction and even treatment discontinuation if the pain syndrome resolves. However, about 20% of patients with cancer are at...
How the PROMISE Study Aims to Convert Multiple Myeloma Into a Preventable Cancer
In 2018, researchers from Dana-Farber Cancer Institute launched a large, ambitious screening study called (PROMISE; ClinicalTrials.gov identifier NCT03689595) to identify people with premalignant precursor conditions of multiple myeloma, to understand the molecular signs of progression to myeloma...
MSKCC Awards Young Investigators 2019 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) has named three investigators as the recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes scientists for their accomplishments in the area of cancer research. The winners for 2019 are Nathanael S. Gray, PhD; Joshua...
Your Stories: Behind the Breakthroughs
When Desirée Walker was diagnosed with breast cancer, she considered not treating it—but more frightening to her than the side effects of chemotherapy was missing the chance to watch her children grow. In “Mother Knows Best”—part of the Your Stories Featured Conversations series from Conquer...
New ASCO AnswersFact Sheet on Constipation
Constipation affects about half of all people with cancer. Help patients identify, manage, and cope with this side effect by giving them the ASCO Answers constipation fact sheet. This handout includes an overview of constipation; causes and risks; treatment and management options; a bowel movement...
Using the Nobel Prize to Champion Curiosity-Driven Research in Cancer
William G. Kaelin, Jr, MD, Sidney Farber Professor of Medicine and Howard Hughes Medical Institute Investigator at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, admits that early in his research career, he and his late wife, Carolyn, would have fun...
When to Consider Local Therapy for Stage IV Breast Cancer
Local therapy for stage IV breast cancer has not been proven to increase overall survival, yet there are some cases where local therapy could be considered outside a clinical trial. For patients with intact asymptomatic primary tumors, local therapy could be offered if distant disease is well...
A Diagnosis of Multiple Myeloma Taught Me to Live in the Moment
I was just 39 in 2015 when I was diagnosed with multiple myeloma. I have a wife and three young children whom I love, a challenging and fulfilling career, and I wasn’t ready to die. When I was first diagnosed, I met with a medical oncologist who had little experience treating this type of cancer....
Wake Forest Baptist Awarded $6 Million Grant to Study Web-Based Pain Management Program
For many people who have had cancer, severe pain can persist, even after treatment ends. In an effort to find a nonpharmaceutical approach to pain management for cancer survivors, researchers at Wake Forest Baptist Health have been awarded $6 million from the National Cancer Institute (NCI) to test ...
Oncology Clinicians Play A Role in Telling Patients About the Importance of Exercise
New exercise guidelines for patients with cancer can “improve physical and psychological outcomes from cancer diagnosis and for the balance of life,” concluded representatives from 17 organizations participating in the Second Roundtable on Exercise and Cancer Prevention and Control.1 Attention...
A Call to Action for Oncology Clinicians to Help Patients ‘Move Through Cancer’
“There is clear evidence that patients are more likely to exercise if their oncologist tells them to do so,” reported representatives from 17 organizations participating in the Second Roundtable on Exercise and Cancer Prevention and Control. In an article published in CA: A Cancer Journal for...
Expert Point of View: Charles L. Loprinzi, MD
Charles L. Loprinzi, MD, Regis Professor of Breast Cancer Oncology at the Mayo Clinic, in Rochester, Minnesota, discussed the abstract on oncology massage to treat chemotherapy-induced peripheral neuropathy. He said that although massage therapy shows promise for this patient population, its...
Thomas Gajewski, MD, PhD, Receives 2019 ESMO Award for Immuno-Oncology
The European Society for Medical Oncology (ESMO) has selected Thomas Gajewski, MD, PhD, to receive the 2019 ESMO Award for Immuno-Oncology. The award is given in recognition of his groundbreaking work elucidating why some patients are resistant to immunotherapy and how to restore the anticancer...
An Oncologist’s Thoughtful Examination of Cancer and Personal Loss
“I could not have written this book when I was 30 years old. It is not because of any great discoveries I have made or research papers I have published since. It is because of the experience the intervening decades have given me as I cared for thousands of cancer patients and accompanied many to...
Navneet S. Majhail, MD, MS, Was Inspired by His Father’s Career as a Military Doctor and His Mother’s Battle With Cancer
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Navneet S. Majhail, MD, MS, about his journey from India to the Cleveland Clinic, where he is Director of the Blood and Marrow Transplant Program. He is also President of the American Society for...
Addressing the Obesity Epidemic and Barriers to Implementing Weight Management Programs for Cancer Survivors
Earlier this year, ASCO published the results of its new study on oncologists’ perceptions and practice behaviors regarding obesity, weight management, and related lifestyle factors in their patients both during and after cancer treatment.1 The findings from the online survey of 971 oncology...
Expert Point of View: Richard T. Lee, MD
Richard T. Lee, MD, Associate Professor at Case Comprehensive Cancer Center and University Hospitals Seidman Cancer Center, discussed the abstract by Galloway et al at the 2019 Supportive Care in Oncology Symposium. He remarked that starting a new palliative care consultation can sometimes feel...
ASCO Provides Guidance on Managing Osteoporosis in Cancer Survivors
Cancer survivors are at an increased risk of osteoporotic fractures due to the accelerated loss of bone mineral density as a result of their treatment. Bone loss from cancer therapy is faster and more severe than bone less from aging; rates of bone loss are up to sevenfold higher when they occur...
‘Clinically Meaningful’ Outcomes Seen in Two Studies of First-Line Immunotherapy for Hepatocellular Carcinoma
In the first-line treatment of advanced hepatocellular carcinoma, checkpoint inhibitors led to favorable outcomes in studies reported at the European Society for Medical Oncology (ESMO) Congress 2019—though one study was technically negative. The current first-line standard of care for unresectable ...
Breast Cancer Treatments Targeting Estrogen May Be Putting Patients at Risk for Long-Term Comorbidities
“The majority of breast cancers are hormone receptor–positive, and treatments that target the estrogen receptors are very effective, but they also cause havoc in many tissues that are dependent on estrogen for normal functioning. As a result, breast cancer survivors suffer from ongoing symptoms and ...
ASCO Updates Breast Cancer Risk Reduction Guideline to Include Anastrozole
ASCO has updated a guideline on pharmacologic interventions for breast cancer risk reduction in postmenopausal women at increased risk of developing breast cancer.1 The original clinical practice recommendations for breast cancer risk reduction were published in 1999 and updated in 2002, 2009, and...
Project Socrates: An Educational Bridge From the FDA to the Public
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Jennifer J. Gao, MD, Acting Associate Director of Education in the OCE, and Richard Pazdur, MD, Director of ...
Nivolumab/Ipilimumab: Another First-Line Option for Advanced NSCLC
The combination of nivolumab and ipilimumab improved overall survival compared with chemotherapy as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) expression of at least 1%, according to the results of CheckMate 227....
Role of Voriconazole in Cutaneous Squamous Cell Carcinoma Development
For the last decade, medical experts have known that voriconazole—an antifungal medication used to prevent infections in patients with compromised immune systems—is linked to the development of particularly aggressive squamous cell carcinoma in skin exposed to ultraviolet (UV) rays. However, the...
ESMO Congress 2019: Quick Takes From Key Clinical Trials
The ESMO Congress continues to grow as a pivotal platform for research in clinical oncology. At the ESMO Congress 2019, important findings were showcased in more than 2,200 studies, including 93 late-breaking abstracts. The ASCO Post summarized much of that news in separate articles over several...
Targeted Treatment Advances in Cholangiocarcinoma
For one of the rarest and most aggressive of tumors—cholangiocarcinoma—two novel molecularly targeted agents yielded encouraging outcomes in advanced disease in studies reported at the European Society for Medical Oncology (ESMO) Congress 2019. In the phase III ClarIDHy trial, the risk of disease...
Phase III PROfound Study Evaluates Olaparib in Setting of Metastatic, Castration-Resistant Prostate Cancer
Treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib delayed disease progression and appears to improve survival, compared with newer hormonal agents in men with pretreated metastatic castration-resistant prostate cancer and homologous recombinant repair (HRR) genetic...
Expert Point of View: Pilar Garrido, MD, PhD
At a press conference at the ESMO Congress 2019, Pilar Garrido, MD, PhD, of Ramon y Cajal University Hospital, Madrid, commented on the FLAURA trial: “These results are good news for patients with lung cancer, which is the most common cause of cancer deaths. Advances in the understanding of the...
Neoadjuvant Immunotherapy Plus Chemotherapy Active in Women With Early Triple-Negative Breast Cancer
Immunotherapy has changed the treatment paradigms for melanoma, lung cancer, bladder cancer, and renal cancer. Now, checkpoint inhibitor therapy is making inroads in triple-negative breast cancer—one of the most difficult-to-treat aggressive types of breast cancer. Late-breaking results of the...
New ASCO Answers Fact Sheet on Anxiety and Depression
Anxiety and depression can cause distress and suffering that make it harder to cope with cancer treatment. Help your patients recognize and record their symptoms by giving them the ASCO Answers Anxiety and Depression fact sheet. This handout includes: An overview of anxiety and depression How...
Your Stories: Behind the Breakthroughs
On a Saturday morning, a wife wakes to telling signs that her husband is not well. Before Sunday, a devasting diagnosis comes that a young father has a 1% chance of surviving. The search is on for a life-extending treatment. Erin Miller, who lost her husband, Mike, and Erin’s sister, Dana...
Advocates Urge Action on Cancer Care Access at ASCO Advocacy Summit
At the 2019 ASCO Advocacy Summit, ASCO members from 35 states held more than 160 Congressional meetings, urging members of Congress to take action to advance policy priorities that improve patient access to cancer care, including: The Covering Life-Saving Investigations Needed in Cancer and Other...
Cancer.Net: Physician-Generated Content for Patients With Cancer Worldwide
Receiving a cancer diagnosis is a disorienting moment for our patients who are then faced with making difficult decisions regarding their treatment. In order to improve shared decision-making and to increase patient involvement in their care, it is essential to provide patients and their families...
How Clonal Hematopoiesis of Indeterminate Potential Increases the Risk of Heart Disease and Blood Cancers as People Age
Although stem cells throughout the body acquire genetic mutations over time, usually these alterations do not affect how the stem cells function or cause disease. However, recent research in clonal hematopoiesis and aging has found an association between clonal expansion of hematopoietic cells with ...
Fedratinib: Back From Development Limbo for the Treatment of Myeloproliferative Neoplasms
In September 2019, Dr. Claire Harrison and colleagues, myself among them, presented two new analyses regarding the use of the JAK2 and FLT3 inhibitor fedratinib in myelofibrosis at the Society of Hematologic Oncology (SOHO) Annual Meeting, with resulting publication in Clinical Lymphoma, Myeloma...
The Oncology Care Model and Quality of Care: Defining, Measuring, and Implementing New Approaches to Cancer Care
The Oncology Care Model was instituted in 2016 by the Center for Medicare & Medicaid Innovation as a move away from the fee-for-service payment model and toward value-based care. It has sparked discussion ever since. How should quality be defined? Whose and what values should it reflect? How...
Remembering Craig Alguire
It is with great sadness that we report Craig Alguire, MD, 42, died on October 11, 2019, at his home in Grand Rapids, Michigan. Diagnosed with grade 4 glioblastoma multiforme in 2015, Dr. Alguire chronicled the effects the cancer was having on his life in his Patient’s Corner column, published in...
FDA Awards Research Grants for the Study of Rare Cancers
The U.S. Food and Drug Administration (FDA) recently awarded 12 new clinical trial research grants totaling more than $15 million over the next 4 years, many of them focusing on cancer. Also, the FDA awarded two new research grants for natural history studies in rare diseases, totaling more than...
